ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 300 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 1.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $124,862,422 | -13.0% | 5,991,479 | 0.0% | 4.21% | +19.8% |
| Q2 2023 | $143,495,922 | +27.3% | 5,991,479 | 0.0% | 3.52% | -3.2% |
| Q1 2023 | $112,759,635 | +18.2% | 5,991,479 | 0.0% | 3.63% | +25.1% |
| Q4 2022 | $95,384,346 | -2.7% | 5,991,479 | 0.0% | 2.90% | +0.3% |
| Q3 2022 | $98,021,000 | +16.1% | 5,991,479 | 0.0% | 2.89% | -0.7% |
| Q2 2022 | $84,420,000 | -41.8% | 5,991,479 | 0.0% | 2.91% | -35.8% |
| Q1 2022 | $145,114,000 | +103.1% | 5,991,479 | +95.8% | 4.54% | +99.4% |
| Q4 2021 | $71,434,000 | +988.4% | 3,060,593 | +2160.2% | 2.28% | +369.3% |
| Q2 2020 | $6,563,000 | -52.0% | 135,413 | -58.2% | 0.48% | -66.1% |
| Q1 2020 | $13,684,000 | -36.0% | 323,889 | -35.2% | 1.43% | -25.8% |
| Q4 2019 | $21,390,000 | – | 500,000 | – | 1.93% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |